Theravectys

TheraVectys is a clinical-stage biotech pioneering a lentiviral vector-based vaccine platform designed to induce potent and durable T cell immunity. Its lead program, Lenti-HPV-07, is a therapeutic vaccine for HPV-induced cancers currently in Phase I/IIa trials, with a pipeline spanning oncology and infectious diseases. The company holds an exclusive worldwide license from Institut Pasteur for its core technology and has demonstrated compelling preclinical efficacy, including 100% tumor eradication in HPV models and complete protection against SIV in non-human primates.

Proprietary lentiviral vector platform designed for in vivo targeting of dendritic cells to induce potent and durable antigen-specific T cell immunity for both prophylactic and therapeutic applications.

TheraVectys competes in the crowded fields of cancer immunotherapy and novel vaccine platforms, facing competition from other viral vectors (adeno-, AAV), mRNA technologies, and cell-based therapies. Its differentiation lies in the specific in vivo targeting of dendritic cells via lentiviral vectors to generate strong T cell responses.